530 related articles for article (PubMed ID: 26637696)
21. Treatment of Acquired Sideroblastic Anemias.
Mangaonkar AA; Patnaik MM
Hematol Oncol Clin North Am; 2020 Apr; 34(2):401-420. PubMed ID: 32089219
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Pediatr Int; 2013 Dec; 55(6):675-9. PubMed ID: 24003969
[TBL] [Abstract][Full Text] [Related]
23. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
24. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
25. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
[TBL] [Abstract][Full Text] [Related]
26. X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguise.
Donker AE; Raymakers RA; Nieuwenhuis HK; Coenen MJ; Janssen MC; MacKenzie MA; Brons PP; Swinkels DW
Neth J Med; 2014 May; 72(4):210-7. PubMed ID: 24829177
[TBL] [Abstract][Full Text] [Related]
27. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts.
Baumann Kreuziger LM; Wolanskyj AP; Hanson CA; Steensma DP
Eur J Haematol; 2011 Jun; 86(6):512-6. PubMed ID: 21388451
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
Ohba R; Furuyama K; Yoshida K; Fujiwara T; Fukuhara N; Onishi Y; Manabe A; Ito E; Ozawa K; Kojima S; Ogawa S; Harigae H
Ann Hematol; 2013 Jan; 92(1):1-9. PubMed ID: 22983749
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia.
Cazzola M; Invernizzi R; Bergamaschi G; Levi S; Corsi B; Travaglino E; Rolandi V; Biasiotto G; Drysdale J; Arosio P
Blood; 2003 Mar; 101(5):1996-2000. PubMed ID: 12406866
[TBL] [Abstract][Full Text] [Related]
30. New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine.
Kucerova J; Horvathova M; Mojzikova R; Belohlavkova P; Cermak J; Divoky V
Acta Haematol; 2011; 125(4):193-7. PubMed ID: 21252495
[TBL] [Abstract][Full Text] [Related]
31. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia.
Guernsey DL; Jiang H; Campagna DR; Evans SC; Ferguson M; Kellogg MD; Lachance M; Matsuoka M; Nightingale M; Rideout A; Saint-Amant L; Schmidt PJ; Orr A; Bottomley SS; Fleming MD; Ludman M; Dyack S; Fernandez CV; Samuels ME
Nat Genet; 2009 Jun; 41(6):651-3. PubMed ID: 19412178
[TBL] [Abstract][Full Text] [Related]
32. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts.
del Rey M; Benito R; Fontanillo C; Campos-Laborie FJ; Janusz K; Velasco-Hernández T; Abáigar M; Hernández M; Cuello R; Borrego D; Martín-Zanca D; De Las Rivas J; Mills KI; Hernández-Rivas JM
PLoS One; 2015; 10(5):e0126555. PubMed ID: 25955609
[TBL] [Abstract][Full Text] [Related]
33. [Familial pyridoxine-responsive sideroblastic anaemia. One case (author's transl)].
Garbarz M; Bernard JF; Boivin P
Nouv Presse Med; 1980 Nov; 9(44):3345-7. PubMed ID: 7443486
[TBL] [Abstract][Full Text] [Related]
34. Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options.
Abu-Zeinah G; DeSancho MT
J Blood Med; 2020; 11():305-318. PubMed ID: 33061728
[TBL] [Abstract][Full Text] [Related]
35. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia.
Fujiwara T; Harigae H
Free Radic Biol Med; 2019 Mar; 133():179-185. PubMed ID: 30098397
[TBL] [Abstract][Full Text] [Related]
37. [Ring sideroblasts and iron metabolism].
Fujiwara T
Rinsho Ketsueki; 2020; 61(7):770-778. PubMed ID: 32759564
[TBL] [Abstract][Full Text] [Related]
38. [Recent advances in the knowledge of sideroblastic anemia].
Fujiwara T
Rinsho Ketsueki; 2022; 63(6):600-607. PubMed ID: 35831194
[TBL] [Abstract][Full Text] [Related]
39. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias.
Peoc'h K; Nicolas G; Schmitt C; Mirmiran A; Daher R; Lefebvre T; Gouya L; Karim Z; Puy H
Mol Genet Metab; 2019 Nov; 128(3):190-197. PubMed ID: 30737140
[TBL] [Abstract][Full Text] [Related]
40. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
